Your trusted source for investing success

Tag: abbott laboratories

Abbott offers EU concessions over $25 billion St. Jude deal

Reuters reported that Abbott Laboratories (NYSE:ABT) has offered concessions for its $25 billion bid for St. Jude Medical (NYSE:STJ).

As quoted in the article:
The move pushed back the European Commission’s decision on the deal to Nov. 21 from Nov. 9, according to a filing on the EU competition enforcer’s website on

The New Age of Glucose Monitoring

The New Age of Glucose Monitoring

From contact lenses that measure glucose levels to wireless sensors that read them through the skin, blood sugar monitoring is undergoing a major reinvention. But why are medical device companies investing so much into diabetes management specifically?

St. Jude Medical Files Lawsuit in Midst of Acquisition

St. Jude Medical Files Lawsuit in Midst of Acquisition

St. Jude Medical saw its stock fall four percent after Muddy Waters published a report alleging that the medical device manufacturer had serious cyber security issues. Now, St. Jude is striking back with a lawsuit its CEO calls “critical to the entire medical device ecosystem.”

Global Transcatheter Mitral Valve Replacement (TMVR) Market: Size & Forecasts (2016-2021) – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global
Transcatheter Mitral Valve Replacement (TMVR) Market: Size & Forecasts
(2016-2021)” report to their offering.

Currently, the global TMVR market is in early stage, but it is expected
to increase at high growth rates during the forecasted period
(2016-2021). The global TMVR market is supported

Roger Ulrich Joins Board of Remedy Pharmaceuticals

NEW YORK–(BUSINESS WIRE)–Remedy Pharmaceuticals, a privately-held pharmaceutical company focused
on bringing life-saving hospital-based treatment to people affected by
central nervous system (CNS) related edema, today announced that Roger
Ulrich has joined the company’s board of directors.

In 2006 Dr. Ulrich co-founded Calistoga Pharmaceuticals, which was
acquired by Gilead Sciences (NASDAQ:GILD) in 2011 in a transaction
valued

XBiotech Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Company’s Extensive Product Portfolio

AUSTIN, Texas, June 08, 2016 (GLOBE NEWSWIRE) — XBiotech (NASDAQ:XBIT), the developer of True Human™ therapeutic antibodies, announced today that Trey Benson has joined the company as Commercial Head, effective June 6. Benson has more than two decades of global healthcare experience, with over 16 years of marketing and commercial

Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis

CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.–(BUSINESS WIRE)–The Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) has adopted a positive opinion
recommending the granting of a marketing authorization for ZINBRYTA™
(daclizumab) intended for the treatment of relapsing forms of multiple
sclerosis (RMS), Biogen
(NASDAQ: BIIB) and AbbVie (NYSE:
ABBV) announced today. ZINBRYTA is

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
How to Invest in Cardiovascular Disease Treatments

URL: https://investingnews.com/daily/life-science-investing/medical-device-investing/how-to-invest-in-cardiovascular-disease-treatments/